Matinas BioPharma Holdings, Inc. financial data

Symbol
MTNB on NYSE
Industry
Pharmaceutical Preparations
Location
1545 Route 206 South, Suite 302, Bedminster, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 579 % -34.9%
Debt-to-equity 30.5 % +37.9%
Return On Equity -123 % -74%
Return On Assets -94.3 % -62.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.09M shares -97.7%
Common Stock, Shares, Outstanding 5.09M shares -97.7%
Entity Public Float 75.9M USD -53.9%
Common Stock, Value, Issued 1K USD -95.5%
Weighted Average Number of Shares Outstanding, Basic 5.04M shares +15.9%
Weighted Average Number of Shares Outstanding, Diluted 5.04M shares +15.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.1M USD
Research and Development Expense 12.7M USD -13.4%
General and Administrative Expense 9.29M USD -14.2%
Costs and Expenses 22M USD -13.8%
Operating Income (Loss) -22M USD +5.78%
Net Income (Loss) Attributable to Parent -21.1M USD +0.61%
Earnings Per Share, Basic 0.44 USD/shares +38.8%
Earnings Per Share, Diluted 0.44 USD/shares +38.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.3M USD +60.7%
Marketable Securities, Current 500K USD -95.8%
Assets, Current 11.7M USD -41.3%
Property, Plant and Equipment, Net 1.65M USD -18.5%
Operating Lease, Right-of-Use Asset 2.62M USD -18.3%
Intangible Assets, Net (Excluding Goodwill) 3.02M USD 0%
Goodwill 1.34M USD 0%
Assets 20.6M USD -30.9%
Accounts Payable, Current 349K USD -58.2%
Employee-related Liabilities, Current 510K USD +5.81%
Accrued Liabilities, Current 1.04M USD -41%
Contract with Customer, Liability, Current 721K USD
Liabilities, Current 2.12M USD -34.2%
Deferred Income Tax Liabilities, Net 341K USD 0%
Operating Lease, Liability, Noncurrent 2.32M USD -24%
Liabilities 4.8M USD -27.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -51K USD +90.1%
Retained Earnings (Accumulated Deficit) -191M USD -12.4%
Stockholders' Equity Attributable to Parent 15.8M USD -31.8%
Liabilities and Equity 20.6M USD -30.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.77M USD -41.2%
Net Cash Provided by (Used in) Financing Activities 53K USD
Net Cash Provided by (Used in) Investing Activities 2M USD -33.3%
Common Stock, Shares Authorized 250M shares -50%
Common Stock, Shares, Issued 5.09M shares -97.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.72M USD -241%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.99M USD -69.4%
Deferred Tax Assets, Valuation Allowance 40.8M USD +18.7%
Deferred Tax Assets, Gross 40.5M USD +18.9%
Operating Lease, Liability 3.05M USD -17.2%
Payments to Acquire Property, Plant, and Equipment 545K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.8M USD -0.42%
Lessee, Operating Lease, Liability, to be Paid 3.64M USD -20.6%
Property, Plant and Equipment, Gross 3.62M USD -1.63%
Operating Lease, Liability, Current 733K USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.04M USD +4.21%
Lessee, Operating Lease, Liability, to be Paid, Year One 998K USD +4.39%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 586K USD -34.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 944K USD -9.23%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 273K USD -71.1%
Additional Paid in Capital 207M USD +6.93%
Depreciation, Depletion and Amortization 94K USD +1.08%
Share-based Payment Arrangement, Expense 1.41M USD +33.2%